Development of aptamers against unpurified proteins

Abstract

SELEX (Systematic Evolution of Ligands by EXponential enrichment) has been widely used for the generation of aptamers against target proteins. However, its requirement for pure target proteins remains a major problem in aptamer selection, as procedures for protein purification from crude bio-samples are not only complicated but also time and labor consuming. This is because native proteins can be found in a large number of diverse forms because of posttranslational modifications and their complicated molecular conformations. Moreover, several proteins are difficult to purify owing to their chemical fragility and/or rarity in native samples. An alternative route is the use of recombinant proteins for aptamer selection, because they are homogenous and easily purified. However, aptamers generated against recombinant proteins produced in prokaryotic cells may not interact with the same proteins expressed in eukaryotic cells because of posttranslational modifications. Moreover, to date recombinant proteins have been constructed for only a fraction of proteins expressed in the human body. Therefore, the demand for advanced SELEX methods not relying on complicated purification processes from native samples or recombinant proteins is growing. This review article describes several such techniques that allow researchers to directly develop an aptamer from various unpurified samples, such as whole cells, tissues, serum, and cell lysates. The key advantages of advanced SELEX are that it does not require a purification process from a crude bio-sample, maintains the functional states of target proteins, and facilitates the development of aptamers against unidentified and uncharacterized proteins in unpurified biological samples.

A Novel Quality Control Methodology on Screening out for Human Osteosarcoma Cell Adaptor Based on the Cell-SELEX Technique

“…OS has strong invasiveness and metastasis [17]. The inducing factors include trauma and stimulation, viral infection, exposure to radioactive substances, and Rb gene abnormalities [18]. It is necessary to differentiate brosarcoma, especially bone brosarcoma in the process of clinical diagnosis [19].…”

Whole‐bacterium ribosome display selection for isolation of highly specific anti‐Staphyloccocus aureus Affitins for detection‐ and capture‐based biomedical applications

“…Third, the process takes place in a tube, and subtractive or competitive selections by ribosome display can be made by alternating different bacterial strains (or obtained under different culture conditions) or by using a ligand to mask an unwanted epitope. Other selection technics have been used to select binders against whole‐cells such as phage display and SELEX (Goto, Tsukakoshi, & Ikebukuro, ; Stark, Venet, & Schmid, ). However, none of them allow to combine manipulation of so large libraries (up to 10 12 /10 13 variants) and in vitro selection of polypeptides as ribosome display does.…”